Syndax Pharmaceuticals Inc SNDX
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2016-03-03 |
| Shares Out. | 88,610,000 |
| Website | syndax.com/ ↗ |
| Phone | 13026365400 |
| Employees | 298 |
| Revenue | $64.9M |
| Gross Profit | $62.2M |
| Net Income | -$42.7M |
| Free Cash Flow | -$120.0M |
| Total Assets | $472.7M |
| Total Liabilities | $431.0M |
| Equity | $41.6M |
About Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Syndax Pharmaceuticals Inc is a publicly traded company under the ticker symbol SNDX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
20 analysts (2026-07-01)